AMPD1 (C34T) polymorphism and clinical outcomes in patients undergoing myocardial revascularization

International Journal of Cardiology

Volumn 101, Issue 2, 2005, Pages 191-195

  Andreassi, Maria Grazia ^a,c   Botto, Nicoletta ^a   Laghi Pasini, Franco ^b   Manfredi, Samantha ^a   Ghelarducci, Bruno ^a   Farneti, Andrea ^a   Solinas, Marco ^a   Biagini, Andrea ^a   Picano, Eugenio ^a  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c G PASQUINUCCI HOSPITAL   (Italy)

Author keywords

AMPD1 gene; CABG; Clinical outcomes; Coronary artery disease; PTCA

Indexed keywords

ADENOSINE; ADENOSINE MONOPHOSPHATE DEAMINASE;

ADULT; AGED; ALLELE; ANGINA PECTORIS; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; HEART EJECTION FRACTION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MYOCARDIAL DISEASE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADENOSINE; AGED; AMP DEAMINASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TREATMENT OUTCOME;

EID: 18344391205     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.03.014     Document Type: Article

References (22)

1. Morisaki T., Sabina R.L., Holmes E.W. Adenylate deaminase: a multigene family in humans and rats. J. Biol. Chem. 265:1990;11482-11486
2. Sabina R.L., Holmes E.W. Myoadenylate deaminase deficiency. Scriver C.R., Beaudet A.L., Sly W.S., Valle D. The Metabolic and Molecular Bases of Inherited Disease. 1995;1769-1780 McGraw-Hill, New York
3. Morisaki T., Gross M., Morisaki H., Pongtratz G., Zollner N., Holmes E.W. Molecular basis of AMP deaminasi deficiency in skeletal muscle. Proc. Natl. Acad. Sci. U. S. A. 89:1992;6457-6461
4. Loh E., Rebbeck T.R., Mahoney P.D., DeNofrio D., Swain J.L., Holmes E.W. Common variant in AMPD1 gene predicts improved clinical outcome in patients with heart failure. Circulation. 99:1999;1422-1425
5. Anderson J.L., Habashi J., Carlquist J.F., et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. JACC. 36:2000;1248-1252
6. Pomerantz B., Joo K., Shames B.D., Cleveland J.C., Banerjee A., Harken A.H. Adenosine preconditioning reduces both pre and postischemic arrhythmia in human myocardium. J. Surg. Res. 90:2000;191-196
7. Marzilli M., Orsini E., Marraccini P., Testa R. Beneficial effects of intracoronary adenosine as an adjunct to primary angioplasty in acute myocardial infarction. Circulation. 101:2000;2154-2159
8. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed.:1989;CSH, USA
9. Laghi-Pasini F., Guideri F., Petersen C., et al. Blunted increase in plasma adenosine levels following dipyridamole stress in dilated cardiomyopathy patients. J. Intern. Med. 254:2003;591-596
10. Sabina R.L., Ogasawara N., Holmes E.W. Expression of three stage-specific transcript of AMP deaminase during myogenesis. Mol. Cell. Biol. 9:1989;2244-2246
11. Sabina R.L., Fishbein W.N., Pezeshkpour G., Clarke P.R., Holmes E.W. Molecular analysis of the myoadenilate deaminase deficiencies. Neurology. 42:1992;170-179
12. Kelemen J., Rice D.R., Bradley W.G., Munsat T.L., DiMauro S., Hogan E.L. Familial myoadenylate deaminase deficiency and exertional myalgia. Neurology. 32:1982;857-863
13. Sinkeler S.P., Joosten E.M., Wevers R.A., et al. Myoadenylate deaminase deficiency: a clinical, genetic, and biochemical study in nine families. Muscle Nerve. 11:1988;312-317
14. Sabina R.L., Swain J.L., Olanow C.W., et al. Myoadenylate deaminase deficiency. Functional and metabolic abnormalities associated with disruption of the purine nucleotide cycle. J. Clin. Invest. 73:1984;720-730
15. Feldman A., Wagner D., McNamara D. AMPD1 gene mutation in congestive heart failure. New insights into the pathophysiology of disease progression. Circulation. 99:1999;1397-1399
16. Picano E., Abbracchio M.P. Adenosine, the imperfect endogenous anti-ischemic cardio-neuroprotector. Brain Res. Bull. 52:2000;75-82
17. Kalsi K.K., Yuen A.H., Rybakowska I.M., et al. Decreased cardiac activity of AMP deaminase in subjects with the AMPD1 mutation - a potential mechanism of protection in heart failure. Cardiovasc Res. 59:2003;678-684
18. Tarnopolsky M.A., Parise G., Gibala M.J., Graham T.E., Rush J.W. Myoadenylate deaminase deficiency does not affect muscle anaplerosis during exhaustive exercise in humans. J. Physiol. 533:2001;881-889
19. Taubert G., Winkler R., Senges J., et al. AMPD1 gene polymorphism presents no differences in coronary artery disease severity and related complications compared to AMPD1 gene wild type in 3258 invasively investigated patients. 23th Congress of the European Society of Cardiology, Stockholm, September:2001;. [abstract 989]
20. Morisaki H., Morisaki T., Kariko K., Genetta T., Holmes E.W. Positive and negative elements mediate control of alternative splicing in the AMPD1 gene. Gene. 246:2000;365-372
21. Morisaki H., Morisaki T., Newby L.K., Holmes E.W. Alternative splicing: a mechanism for phenotypic rescue of a common inherited defect. J. Clin. Invest. 91:1993;2275-2280
22. Gross M., Rötzer E., Kölle P., et al. A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul. Disord. 12:2002;558-565